Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berubicin - Reata Pharmaceuticals

Drug Profile

Berubicin - Reata Pharmaceuticals

Alternative Names: Berubicin (B); Berubicin hydrochloride; Reata 744; RTA 744; WP744

Latest Information Update: 26 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Reata Pharmaceuticals
  • Class Anthracyclines; Antineoplastics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Neoplastic meningitis

Most Recent Events

  • 26 Mar 2018 CNS Pharmaceuticals plans a phase IIa trial for Glioblastoma
  • 01 Dec 2017 CNS Pharmaceuticals and Reata Pharmaceuticals agree to develop berubicin for Glioblastoma
  • 16 Apr 2008 Interim efficacy, adverse events and pharmacokinetics data from a Phase-I trial in Glioblastoma presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top